Baxter Healthcare Corporation et al v. Becton, Dickinson, and Company, No. 3:2017cv02186 - Document 78 (S.D. Cal. 2021)
Court Description: ORDER Denying 72 Motion to Lift Stay as to U.S. Patent No. 8,554,579. Signed by Judge Janis L. Sammartino on 1/4/2021. (tcf)
Download PDF
<![CDATA[
Baxter Healthcare Corporation et al v. Becton, Dickinson, and Company Doc. 78 Case 3:17-cv-02186-JLS-RBB Document 78 Filed 01/04/21 PageID.1765 Page 1 of 8 1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 11 12 BAXTER HEALTHCARE CORPORATION and BAXTER CORPORATION ENGLEWOOD, Case No.: 3:17-cv-2186 JLS-RBB ORDER DENYING MOTION TO LIFT STAY AS TO U.S. PATENT NO. 8,554,579 13 Plaintiffs, 14 15 16 17 v. (ECF No. 72) BECTON, DICKINSON AND COMPANY 18 Defendant. 19 20 21 Presently before the Court is Plaintiffs Baxter Healthcare Corporation and Baxter 22 Healthcare Englewood’s Motion to Lift Stay Regarding U.S. Patent No. 8,554,579. 23 (“Mot.,” ECF No. 72). Also before the Court is Defendant Becton, Dickinson and 24 Company’s Opposition to the Motion (“Opp’n,” ECF No. 73) and Plaintiffs’ Reply in 25 Support of the Motion, (“Reply,” ECF No. 76). The Court took this matter under 26 submission without oral argument. 27 considered the Parties’ arguments and the relevant law, the Court DENIES Plaintiffs’ 28 Motion to Lift Stay. See generally ECF No. 77. Having carefully 1 3:17-cv-2186 JLS-RBB Dockets.Justia.com Case 3:17-cv-02186-JLS-RBB Document 78 Filed 01/04/21 PageID.1766 Page 2 of 8 1 BACKGROUND 2 Plaintiffs develop and manufacture renal and medical products, including pharmacy 3 automation, software and services, acute renal care, home and in-center dialysis, sterile IV 4 solutions, infusion systems and devices, parenteral nutrition, biosurgery products and 5 anesthetics, and perioperative care. Complaint (“Compl.,” ECF No. 1) ¶ 26. Defendant is 6 “a global medical technology company that manufactures and sells medical supplies, drug 7 delivery systems, laboratory equipment, software solutions, and diagnostic systems.” Id. 8 ¶ 32. Plaintiffs are both the assignee and owner of three United States patents: No. 9 8,554,579 (the ’579 patent), issued October 8, 2013, id. ¶ 17; Ex. A, ECF No. 1-3; No. 10 9,474,693 (the ’693 patent), issued October 25, 2016, Compl. ¶ 18; Ex. B, ECF No. 1-4; 11 and No. 9,662,273 (the ’273 patent), issued May 30, 2017, Compl. ¶ 19; Ex. C, ECF No. 12 1-5. 13 The ’579 patent generally claims a “management of medication dose orders and 14 medication dose preparation,” and, more specifically, “remote dose inspection for 15 facilitating the practice of telepharmacy.” Ex. A at 1:14–20. The ’579 specification 16 explains that “a pharmacist by law has to approve each drug order before it can be released 17 and delivered to a patient,” id. at 3:6–7, and States impose a variety of regulations for “the 18 level of supervision required by a pharmacist in monitoring and approving drugs prepared 19 by others,” id. at 3:8–12. Generally, pharmacists “may be able to approve a drug order and 20 release it even if the pharmacist is in a different room of the same building,” id. at 3:12– 21 14, but an issue arises when a “pharmacist is temporarily unavailable,” id. at 3:20. The 22 ’579 patent addresses this issue by “provid[ing] a portal for remote inspection of prepared 23 doses and thus facilitat[ing] the practice of telepharmacy, by which a pharmacist can 24 inspect the dose preparation from any location inside the hospital or elsewhere so that doses 25 are released more quickly and efficiently.” Id. at 20:58–63. 26 The ’693 patent shares the same specification with its continuation, the ’273 patent. 27 Similar to the ’579 patent, the ’693 and ’273 patents generally cover “[e]mbodiments of 28 medical dose preparation management systems that may assist in management of medical 2 3:17-cv-2186 JLS-RBB Case 3:17-cv-02186-JLS-RBB Document 78 Filed 01/04/21 PageID.1767 Page 3 of 8 1 doses.” Ex. C at 2:38–39. The common specification explains that “medical doses may 2 be required to be verified by a pharmacist prior to being dispensed from the pharmacy for 3 administration to a patient.” Id. at 1:39–41. A problem arises when a pharmacist must 4 “physically observe the materials associated with the dose order” because the pharmacist 5 may need to enter a “clean room” to verify the dose preparation. Id. at 1:54–56. 6 PROCEDURAL BACKGROUND 7 On October 26, 2017, Plaintiffs filed a Complaint alleging infringement of the ’579, 8 ’693, and ’273 patents. See generally ECF No. 1. On November 12, 2018, Defendant filed 9 a Motion to Stay pending the Patent Trial and Appeal Board’s (“PTAB”) resolution of inter 10 partes review (“IPR”) petitions filed by Defendant on the three patents. See generally ECF 11 No. 45. Plaintiffs initially filed an Opposition, see generally ECF No. 54, and Defendant 12 filed a Reply, see generally ECF No. 57. However, on May 3, 2019, the PTAB issued 13 decisions instituting trial on all claims challenged in the three IPR petitions. See ECF No. 14 68 at 1. Based on these developments, Plaintiffs did not oppose a renewed Motion to Stay 15 this action. Id. On May 20, 2019, Defendant filed a renewed unopposed Motion to Stay 16 pending IPR “through final exhaustion of the IPR proceeding, including any appeal.” Id. 17 The Court granted Defendant’s Unopposed Motion to Stay conditioned on the exhaustion 18 of any appeals. See generally ECF No. 69. 19 The PTAB issued its Final Written Decision on May 3, 2019, concluding that all 20 claims of the ‘579 Patent were patentable and that the ‘693 and ‘273 patents were 21 unpatentable. Mot. at 2–3. The Parties have now appealed all three of the PTAB’s 22 decisions. See Opp’n at 7 (citing Becton, Dickinson & Co. v. Baxter Corp. Englewood, 23 No. IPR2019-00121, Paper 64 (P.T.A.B. May 11, 2020); Becton, Dickinson & Co. v. 24 Baxter Corp. Englewood, No. IPR2019-00120, Paper 64 (PTAB May 11, 2020); Becton, 25 Dickinson & Co. v. Baxter Corp. Englewood, No. IPR2019-00119, Paper 52 (P.T.A.B. 26 June 18, 2020)). Plaintiffs now file this instant Motion seeking to lift the stay as to the 27 ‘579 patent only. See generally Mot. 28 /// 3 3:17-cv-2186 JLS-RBB Case 3:17-cv-02186-JLS-RBB Document 78 Filed 01/04/21 PageID.1768 Page 4 of 8 1 LEGAL STANDARD 2 “[A] court that imposes a stay of litigation has the inherent power and discretion to 3 lift the stay.” Ho Keung Tse v. Apple, Inc., No. C 06-06573 SBA, 2013 WL 5302587, at 4 *2 (N.D. Cal. Sept. 19, 2013) (quoting Canady v. Erbe Elektromedizin GMBH, 271 F. 5 Supp. 2d 64, 74 (D.D.C. 2002)). “A court may lift a stay if the circumstances supporting 6 the stay have changed such that the stay is no longer appropriate.” Murata Mach. USA v. 7 Daifuku Co., 830 F.3d 1357, 1361 (Fed. Cir. 2016) (citing Canady, 271 F. Supp. 2d at 74). 8 When determining whether to lift a stay, the court analyzes the same three-factor test which 9 informed whether the stay was appropriate in the first place: “(1) whether discovery is 10 complete and whether a trial has been set; (2) whether a stay will simplify the issues in 11 question and trial of a case; and (3) whether the stay would unduly prejudice or present a 12 clear tactical disadvantage to the nonmoving party.” Pi-Net Int’l, Inc. v. Focus Bus. Bank, 13 No. 5:12-CV-04958-PSG, 2015 WL 1538259, at *3 (N.D. Cal. Apr. 6, 2015). In addition 14 to these factors, a court should consider the “totality of the circumstances.” Universal 15 Elecs., Inc. v. Universal Remote Control, Inc., 943 F. Supp. 2d 1028, 1031 (C.D. Cal. 2013) 16 (citing Allergan Inc. v. Cayman Chem. Co., No. SACV 07–01316 JVS (RNBx), 2009 WL 17 8591844, at *2 (C.D. Cal. Apr. 9, 2009). 18 19 ANALYSIS I. Stage of the Proceedings 20 The Court finds the early stage in the proceedings weighs against lifting the stay. If 21 discovery has not been completed and a trial date has not been set, the first factor typically 22 weighs against lifting the stay. 23 212CV02319TLNEFB, 2016 WL 5159524, at *2 (E.D. Cal. Sept. 21, 2016); Target 24 Therapeutics, Inc. v. SciMed Life Sys., Inc., 33 U.S.P.Q.2d 2022, 2023 (N.D. Cal. 1995) 25 (holding that the absence of “significant discovery” or “substantial expense and time . . . 26 invested” in the litigation weighed in favor of staying the litigation). Smart Modular Techs., Inc. v. Netlist, Inc., No. 27 When the Court granted the stay in this case on May 21, 2019, the litigation had not 28 progressed past the early stages. See generally ECF No. 69. This has not changed during 4 3:17-cv-2186 JLS-RBB Case 3:17-cv-02186-JLS-RBB Document 78 Filed 01/04/21 PageID.1769 Page 5 of 8 1 the duration of the stay. Little discovery has been completed in this case, the Court has not 2 yet issued a scheduling order, and the Court has not held an Early Neutral Evaluation 3 Conference. Opp’n at 13 (citing ECF No. 57 at 2); see Robert Bosch Healthcare Sys., Inc. 4 v. Cardiocom LLC, No. 14-CV-01575-EMC, 2017 WL 6939167, at *1 (N.D. Cal. Mar. 16, 5 2017) (finding the first factor “necessarily favors maintaining the stay, as the case has been 6 frozen at the same early stage it was at when the Court first entered the stay”); Evolutionary 7 Intelligence, LLC v. Livingsocial, Inc., No. 13-CV-04205-WHO, 2014 WL 2735185, at *2 8 (N.D. Cal. June 16, 2014) (finding the first factor favored the stay because only limited 9 discovery had occurred, no pretrial dates had been scheduled, and no claim construction or 10 other substantive briefs had been filed or scheduled). 11 Accordingly, the first factor disfavors lifting the stay as this case is still in the early 12 stages. 13 II. Simplification of Issues 14 The Court finds lifting the stay at this juncture could introduce complications into 15 the case, and therefore this factor weighs against lifting the stay. “One purpose of the 16 reexamination procedure is to eliminate trial of that issue (when the claim is canceled) or 17 facilitate trial of that issue by providing the district court with the expert view of the PTO 18 (when a claim survives the reexamination proceeding).” Gould v. Control Laser Corp., 19 705 F.2d 1340, 1342 (Fed. Cir. 1983). 20 The Federal Circuit’s decision of the appeal as to all three patents will simplify the 21 issues at trial. The Federal Circuit’s review could render the entirety of the Plaintiffs’ case 22 moot if the court finds that the PTAB erred in its findings on the ‘573 patent while affirming 23 the PTAB’s findings of invalidity on the other two patents. Alternatively, if the Federal 24 Circuit finds one or both of the other patents to be valid and enforceable, the potential for 25 separate infringement suits of related technology in this Court will duplicate the discovery 26 process and expend unnecessary resources. See, e.g., Evolutionary Intelligence, 2014 WL 27 2735185, at *3 (concluding that, where the patents are related, “[l]itigating the . . . ’682 28 patent now and the ’536 patent following resolution of the IPR would be inefficient and 5 3:17-cv-2186 JLS-RBB Case 3:17-cv-02186-JLS-RBB Document 78 Filed 01/04/21 PageID.1770 Page 6 of 8 1 may result in duplication of effort”); Sonics, Inc. v. Arter is, Inc., 2013 WL 503091, at *3 2 (N.D. Cal. Feb. 8, 2013) (“When there are overlapping issues between the reexamined 3 patents and other non-reexamined patents-in-suit, courts have found that staying the entire 4 case is warranted.”); Methode Elec., Inc. v. Infineon Technologies Corp., 2000 WL 5 35357130, at *3 (N.D. Cal. Aug. 7, 2000) (“Duplicative discovery may result if only the 6 ‘408 patent is stayed since there are likely to be common documents and witnesses 7 regarding the infringement litigation of the ‘408 and ‘468 patents.”); Pragmatus Telecom, 8 LLC v. NETGEAR, Inc., 2013 WL 2051636, at *2 (N.D. Cal. May 14, 2013) (“[A] stay 9 request is not contingent upon the reexamination proceeding being coterminous and 10 resolving every claim and issue in this action. Rather, the salient question is whether the 11 reexamination will aid the Court or otherwise streamline the litigation.”). 12 Plaintiffs argue that the Federal Circuit has a high affirmance rate of PTAB 13 decisions, and therefore the potential outcome of the appeal is too speculative to justify a 14 stay. Mot. at 7. Some courts have found this argument to be persuasive. See Elm 3DS 15 Innovations, LLC v. Samsung Elecs. Co., No. CV 14-1430-LPS-CJB, 2018 WL 1061370, 16 at *2 (D. Del. Feb. 26, 2018) (“[W]hile it is of course possible that the Federal Circuit will 17 come to a different conclusion than did the PTAB, the ‘mere possibility (as opposed to 18 “reasonable likelihood”) that the asserted claims could be invalidated [after an] appeal and 19 [that this would] result in simplification is too speculative to be given much weight.’” 20 (quoting Network–1 Sec. Sols., Inc. v. Alcatel–Lucent USA Inc., CASE NO. 6:11CV492, 21 2015 WL 11439060, at *3 (E.D. Tex. Jan. 5, 2015) (emphasis and alterations in original))). 22 Although the Federal Circuit’s affirmance of the PTAB decisions may be statistically more 23 likely, this outcome is far from a foregone conclusion. In addition to the possibility that 24 any one or more of the PTAB decisions may be overturned, there are other benefits to 25 continuing the stay through the pendency of the appeal. For example, the Federal Circuit’s 26 de novo review of the PTAB’s claim constructions of the patents-in-suit may also provide 27 guidance that will further simplify the issues before this Court. See In re Ameranth Patent 28 Litig. Cases, No. 11CV1810 DMS (WVG), 2015 WL 12868116, at *2 (S.D. Cal. June 4, 6 3:17-cv-2186 JLS-RBB Case 3:17-cv-02186-JLS-RBB Document 78 Filed 01/04/21 PageID.1771 Page 7 of 8 1 2015) (“[I]t makes little sense to have the parties engage in claim construction discovery 2 and briefing, and for the Court to construe claims, when the Federal Circuit may undertake 3 that same task in considering the parties’ appeals.”). 4 The Court finds lifting the stay has the potential to create duplicative discovery and 5 introduce inefficiencies into the case. Therefore, this factor weighs against lifting the stay. 6 III. Undue Prejudice 7 Finally, the Court finds that maintaining the stay will not present a clear 8 disadvantage to either party, so this factor remains neutral. “[D]elay by itself does not 9 necessarily constitute undue prejudice, as nearly every judicial stay involves delay. 10 However, even if such already-occurred delay is not given any weight in this analysis, the 11 additional delay that would be incurred by continuing the stay pending exhaustion of 12 appeals is significant.” Smart Modular Techs., Inc., 2016 WL 5159524, at *3. 13 Although Plaintiffs argue that their damages from loss of market share and 14 opportunities are not readily calculable monetary damages, Mot. at 8, Plaintiffs never 15 sought a preliminary injunction in this case. See Palomar Techs., Inc. v. Mrsi Sys., LLC, 16 No. 15-CV-1484 JLS (KSC), 2016 WL 4496839, at *2 (S.D. Cal. June 14, 2016) 17 (“Plaintiff’s failure to pursue a preliminary injunction undermines its position that 18 monetary damages are insufficient.”). It is true that delaying the suit could limit Plaintiffs’ 19 time to recoup their investment in the ‘579 patent if the Federal Circuit affirms its validity 20 and this Court finds infringement, but the Court finds that Plaintiffs can be adequately 21 compensated by monetary damages for any harm suffered from a continued stay. Compare 22 Smart Modular Techs., Inc., 2016 WL 5159524, at *4 (“[T]he Court agrees that ‘any undue 23 delay in enjoining infringing conduct could cause [the plaintiff] to miss its window for 24 financially capitalizing on its own patented technology.’” (citations omitted)) with Teva 25 Pharm. Int’l GmbH v. Eli Lilly & Co., No. 18-CV12029-ADB, 2019 WL 1767394, at *8 26 (D. Mass. Apr. 22, 2019) (concluding a stay was warranted, even where the parties were 27 competitors, because there was “no indication” that a stay would cause plaintiff “to lose 28 any presently available legal remedies”). 7 3:17-cv-2186 JLS-RBB Case 3:17-cv-02186-JLS-RBB Document 78 Filed 01/04/21 PageID.1772 Page 8 of 8 1 While continuing the stay during the pendency of appeal to the Federal Circuit will 2 increase the duration of the stay, see Mot. at 10, the possibility of appeals from the IPR 3 decisions was expressly contemplated by the parties, Opp’n at 5–6. Significantly, the 4 unopposed motion to stay and the Court’s order granting the motion conditioned the stay 5 on the resolution of any appeal. See ECF No. 69 at 1 (“The stay will automatically extend 6 through final exhaustion of the IPR proceeding, including any appeal.”); but cf. Smart 7 Modular Techs., Inc., 2016 WL 5159524, at *3 (lifting stay when the order granting the 8 initial stay was not conditioned on any exhaustion of appeals). The Court is not persuaded 9 by Plaintiffs’ present argument when Plaintiffs had the opportunity to file an opposition to 10 Defendant’s motion for a stay pending IPR including appeals and chose not to do so. 11 Compare ECF No. 45, with ECF No. 72. The circumstances under which the Court granted 12 the stay have not changed significantly. Akeena Solar Inc. v. Zep Solar Inc., No. C 09- 13 05040 JSW, 2011 WL 2669453, at *2 (N.D. Cal. July 7, 2011) (“Here, litigation is still in 14 its early stages, and the pending reexamination request may eliminate the need for trial 15 completely. Thus lifting the stay would be premature, because the circumstances that led 16 this Court to grant the stay have not changed significantly.”). Therefore, the Court finds 17 this factor is neutral. 18 Considering the totality of the circumstances, the Court finds that the three factors 19 weigh in favor of continuing the stay as to the ‘579 Patent through completion of the IPR 20 proceedings, including the pendency of any appeal. 21 22 CONCLUSION For the foregoing reasons, the Court DENIES Plaintiffs’ Motion to Lift the Stay as 23 to the ‘579 Patent. 24 IT IS SO ORDERED. 25 Dated: January 4, 2021 26 27 28 8 3:17-cv-2186 JLS-RBB
]]>
Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You
should read the full case before relying on it for legal research purposes.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
